Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Surface oncology

- PMLiVE

Second chance for AstraZeneca’s selumetinib with breakthrough designation

Part of R&D and commercial collaboration with MSD

- PMLiVE

NICE green light for Imfinzi in groundbreaking early lung cancer treatment

Early treatment opens up possibility of cure

- PMLiVE

Lynparza scores against pancreatic cancer

AZ and MSD drug success in BRCA-mutated disease

- PMLiVE

More good news, and some bad, for Merck’s Keytruda

A rare setback in phase 3 liver cancer trial

- PMLiVE

Roche’s rival to Bayer’s Vitrakvi gets speedy FDA review

CNS penetration could give edge over rival

- PMLiVE

Advair generics and acquisitions to hit GSK in 2019

Earnings to decline as company transforms

- PMLiVE

GSK upbeat on its return to oncology market

Zejula signals comeback after four year hiatus

- PMLiVE

AstraZeneca unveils reorg, hires controversial José Baselga as cancer chief

Underlines importance of cancer drugs to company's future growth

- PMLiVE

First-line ovarian approval cements AZ’s Lynparza lead

Also new data on recently approved kidney disease drug

- PMLiVE

Horizon Discovery and C4X to harness CRISPR for new cancer drugs

UK companies combine computational and genomic platforms

Live from Singapore: Oncology in APAC – Evaluating the opportunity for novel therapies

Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST

Research Partnership

- PMLiVE

GSK buys cancer firm Tesaro for $5.1bn

Acquisition re-establishes US commercial operations in oncology

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links